Eric Zhi

890 total citations
13 papers, 88 citations indexed

About

Eric Zhi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Eric Zhi has authored 13 papers receiving a total of 88 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in Eric Zhi's work include Advanced Breast Cancer Therapies (7 papers), Protein Degradation and Inhibitors (6 papers) and HER2/EGFR in Cancer Research (5 papers). Eric Zhi is often cited by papers focused on Advanced Breast Cancer Therapies (7 papers), Protein Degradation and Inhibitors (6 papers) and HER2/EGFR in Cancer Research (5 papers). Eric Zhi collaborates with scholars based in United States, Spain and Switzerland. Eric Zhi's co-authors include Rita Nanda, Sara A. Hurvitz, Joanna Opalińska, Anne F. Schott, Adam D. Cohen, Suzanne Trudel, Natalie S. Callander, Hyo S. Han, Ashraf Badros and Ajay K. Nooka and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Eric Zhi

12 papers receiving 86 citations

Peers

Eric Zhi

ONCOL

HEMAT

PRM

RNMI

Helen X Chen United States

Danielle Croucher Canada

Karin H. Herbschleb United Kingdom

Jessica Riceberg United States

Klaus Kirchbacher Austria

Robert Dichmann United States

Paula Proszek United Kingdom

Mark Yan Canada

Ria Uhlig Germany

Reid Shaw United States

Helen X Chen United States

Eric Zhi

71 ×1.2

ONCOL

68 ×1.5

21 ×0.5

HEMAT

19 ×0.8

PRM

6 ×0.5

RNMI

Citations per year, relative to Eric Zhi Eric Zhi (= 1×) peers Helen X Chen

Countries citing papers authored by Eric Zhi

Since Specialization

Citations

This map shows the geographic impact of Eric Zhi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Zhi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Zhi more than expected).

Fields of papers citing papers by Eric Zhi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Zhi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Zhi. The network helps show where Eric Zhi may publish in the future.

Co-authorship network of co-authors of Eric Zhi

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Zhi. A scholar is included among the top collaborators of Eric Zhi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Zhi. Eric Zhi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Hamilton, Erika, Rinath Jeselsohn, Sara A. Hurvitz, et al.. (2024). Abstract PS15-03: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib in ER–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: phase 1b cohort. Cancer Research. 84(9_Supplement). PS15–3. 2 indexed citations

Hamilton, E.P., Nicholas P. McAndrew, Melinda L. Telli, et al.. (2024). 218P Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib (palbo) in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Updated phase Ib cohort results. ESMO Open. 9. 103240–103240. 7 indexed citations

Hurvitz, Sara A., Anne F. Schott, X. Cynthia, et al.. (2024). Abstract PO3-05-08: Updated results from VERITAC evaluating vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in ER–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer. Cancer Research. 84(9_Supplement). PO3–5. 6 indexed citations

Hamilton, Erika, Hyo S. Han, Anne F. Schott, et al.. (2023). 390P Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Update of dose escalation results from a phase I/II trial. Annals of Oncology. 34. S344–S344. 12 indexed citations

Philipovskiy, Alexander, Anne F. Schott, Javier Cortés, et al.. (2023). 256TiP TACTIVE-E: Phase Ib study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in combination with everolimus in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer. ESMO Open. 8(1). 101444–101444. 2 indexed citations

Fasching, Peter A., Katherine Clifton, Ekaterine Arkania, et al.. (2023). 154TiP TACTIVE-N: Open-label, randomized, noncomparative neoadjuvant phase 2 study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, or anastrozole in postmenopausal women with ER+/human epidermal growth factor receptor 2 (HER2)- localized breast cancer. ESMO Open. 8(1). 101493–101493. 3 indexed citations

Hurvitz, Sara A., Anne F. Schott, X. Cynthia, et al.. (2023). 205P VERITAC update: Phase II study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer. ESMO Open. 8(1). 101394–101394. 6 indexed citations

Randall, Leslie M., David M. O’Malley, Bradley J. Monk, et al.. (2022). MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC).. Journal of Clinical Oncology. 40(16_suppl). 5573–5573. 10 indexed citations

Ramalingam, Suresh S., Gilberto de Castro, M.C. Garassino, et al.. (2021). 1360TiP First-line (1L) maintenance therapy with niraparib (nira) + pembrolizumab (pembro) vs placebo + pembro in advanced/metastatic non-small cell lung cancer (NSCLC): Phase III ZEAL-1L study. Annals of Oncology. 32. S1030–S1032. 1 indexed citations

10.

Nooka, Ajay K., Hans C. Lee, Ashraf Badros, et al.. (2020). Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 136(Supplement 1). 22–23. 1 indexed citations

11.

Lonial, Sagar, Ashraf Badros, Suzanne Trudel, et al.. (2020). Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs).. Journal of Clinical Oncology. 38(15_suppl). 8536–8536. 25 indexed citations

12.

Cohen, Adam D., Ajai Chari, Malin Hultcrantz, et al.. (2020). DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment.. Journal of Clinical Oncology. 38(15_suppl). 8519–8519. 13 indexed citations

13.

Hooi, Lai Seong, Muhammad Fadhli Mohd Yusoff, Wan Shakira Rodzlan Hasani, et al.. (2019). SAT-212 Is Chronic Kidney Disease on the rise in Malaysia? Findings from a nationwide study. Kidney International Reports. 4(7). S95–S96.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact